JP2004536077A5 - - Google Patents

Download PDF

Info

Publication number
JP2004536077A5
JP2004536077A5 JP2003501483A JP2003501483A JP2004536077A5 JP 2004536077 A5 JP2004536077 A5 JP 2004536077A5 JP 2003501483 A JP2003501483 A JP 2003501483A JP 2003501483 A JP2003501483 A JP 2003501483A JP 2004536077 A5 JP2004536077 A5 JP 2004536077A5
Authority
JP
Japan
Prior art keywords
composition according
polypeptide
sequence
sequence seq
similarity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003501483A
Other languages
English (en)
Japanese (ja)
Other versions
JP4944360B2 (ja
JP2004536077A (ja
Filing date
Publication date
Priority claimed from EP01401537A external-priority patent/EP1262187A1/en
Application filed filed Critical
Priority claimed from PCT/EP2002/006924 external-priority patent/WO2002098444A2/en
Publication of JP2004536077A publication Critical patent/JP2004536077A/ja
Publication of JP2004536077A5 publication Critical patent/JP2004536077A5/ja
Application granted granted Critical
Publication of JP4944360B2 publication Critical patent/JP4944360B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003501483A 2001-05-25 2002-05-24 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 Expired - Fee Related JP4944360B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP01401377.5 2001-05-25
EP01401377 2001-05-25
EP01401537.4 2001-06-14
EP01401537A EP1262187A1 (en) 2001-05-25 2001-06-14 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EP02290795 2002-03-29
EP02290795.0 2002-03-29
PCT/EP2002/006924 WO2002098444A2 (en) 2001-05-25 2002-05-24 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009006614A Division JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Division JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Publications (3)

Publication Number Publication Date
JP2004536077A JP2004536077A (ja) 2004-12-02
JP2004536077A5 true JP2004536077A5 (enExample) 2012-01-26
JP4944360B2 JP4944360B2 (ja) 2012-05-30

Family

ID=27224392

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003501483A Expired - Fee Related JP4944360B2 (ja) 2001-05-25 2002-05-24 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2009006614A Expired - Lifetime JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Pending JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用
JP2014090333A Expired - Lifetime JP5847231B2 (ja) 2001-05-25 2014-04-24 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009006614A Expired - Lifetime JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Pending JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用
JP2014090333A Expired - Lifetime JP5847231B2 (ja) 2001-05-25 2014-04-24 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Country Status (12)

Country Link
US (4) US7169758B2 (enExample)
EP (2) EP2186524B1 (enExample)
JP (4) JP4944360B2 (enExample)
CN (2) CN101884780B (enExample)
AT (1) ATE427114T1 (enExample)
AU (1) AU2002321105A1 (enExample)
CA (1) CA2448382C (enExample)
CY (1) CY1120241T1 (enExample)
DE (1) DE60231804D1 (enExample)
ES (2) ES2326469T5 (enExample)
TR (1) TR201806761T4 (enExample)
WO (1) WO2002098444A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2186524B1 (en) † 2001-05-25 2018-02-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EP1578254B1 (en) 2002-11-19 2013-03-06 DRG International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
DE10349124A1 (de) 2003-10-22 2005-05-19 Roche Diagnostics Gmbh Differenzialdiagnostik mit Hepcidin
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
KR100679100B1 (ko) * 2004-10-29 2007-02-06 엘지.필립스 엘시디 주식회사 수평 전계 인가형 액정 표시 패널 및 그 제조방법
EP2954903A1 (en) 2005-02-16 2015-12-16 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism
WO2007120883A2 (en) * 2006-04-12 2007-10-25 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
EP2498096A1 (en) * 2006-07-21 2012-09-12 Amgen Inc. Method of detecting and/or measuring hepcidin in a sample
US20090209478A1 (en) 2006-09-21 2009-08-20 Tomoko Nakayama Compositions and methods for inhibiting expression of the hamp gene
US20110053268A1 (en) * 2006-10-17 2011-03-03 Naohisa Tomosugi Method for diagnosis of abnormal iron metabolism using active hepcidin as indicator
PE20130588A1 (es) * 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
WO2008124768A1 (en) 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
US8187827B2 (en) 2007-05-31 2012-05-29 Naohisa Tomosugi Diagnostic methods for acute ischemic disease using activated hepcidin as an indicator
ATE553778T1 (de) 2007-10-02 2012-05-15 Inst Nat Sante Rech Med Für humanes hepcidin spezifische antikörper
US8530619B2 (en) 2007-10-26 2013-09-10 University Of Utah Research Foundation Identification of the hepcidin binding site on ferroportin
PE20091261A1 (es) * 2007-11-02 2009-08-17 Lilly Co Eli Anticuerpos anti-hepcidina
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
UA103032C2 (uk) * 2008-08-06 2013-09-10 Елі Ліллі Енд Компані Селективні антитіла проти гепсидину-25 та їх застосування
US20100068737A1 (en) * 2008-09-16 2010-03-18 University Of Tennessee Research Foundation Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin
CA2742871C (en) 2008-11-13 2018-10-23 Herb Lin Methods and compositions for regulating iron homeostasis by modulation of bmp-6
US8999935B2 (en) * 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
DE102009034150A1 (de) 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
CN102574805A (zh) 2009-08-20 2012-07-11 维福（国际）股份公司 新型喹啉铁调素拮抗剂
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
BR112012005119A2 (pt) 2009-09-07 2016-11-22 Vifor Int Ag novos antagonistas de hepcidina etanodiaminas
WO2011029832A1 (de) 2009-09-09 2011-03-17 Vifor (International) Ag Neue thiazol- und oxazol-hepcidin-antagonisten
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
EP2723861A4 (en) 2011-06-21 2014-12-10 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
WO2013002354A1 (ja) * 2011-06-29 2013-01-03 株式会社ダナフォーム 生体試料の前処理方法、ｒｎａの検出方法及び前処理キット
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
US20160051556A1 (en) 2013-03-21 2016-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US10098878B2 (en) 2014-10-10 2018-10-16 The Board Of Regents Of The University Of Texas System HIF-2α inhibitors for treating iron overload disorders
EP3399996A4 (en) * 2016-01-08 2019-10-16 La Jolla Pharmaceutical Company METHOD FOR THE ADMINISTRATION OF HEPCIDINE
WO2018165186A1 (en) * 2017-03-07 2018-09-13 Intrinsic Lifesciences Llc Assessment of chronic iron deficiency
US20190315821A1 (en) * 2018-02-23 2019-10-17 La Jolla Pharmaceutical Company Compositions comprising hepcidin and methods of use thereof
US12011489B2 (en) 2022-03-30 2024-06-18 Christopher Key Compositions and methods for treating inflammatory disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766207B1 (fr) * 1997-07-11 2000-12-08 Rhone Poulenc Agrochimie Gene chimere codant pour la drosomycine, vecteur le contenant pour la transformation des cellules vegetales et plantes transformees obtenues resistantes aux maladies
FR2770853B1 (fr) * 1997-11-07 1999-12-31 Rhone Poulenc Agrochimie Gene codant pour la thanatine, vecteur le contenant et plantes transformees obtenues resistantes aux maladies
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU3269399A (en) * 1999-03-22 2000-10-09 Universitat Zurich Transforming growth factor (tfg) beta superfamily antagonists
EP2186524B1 (en) 2001-05-25 2018-02-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EP1578254B1 (en) † 2002-11-19 2013-03-06 DRG International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US8017737B2 (en) * 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
EP2954903A1 (en) * 2005-02-16 2015-12-16 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism
CA2664066C (en) * 2006-09-16 2017-04-18 Soy Labs Llc Products and methods using soy peptides to lower total and ldl cholesterol levels
PE20130588A1 (es) † 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
ATE553778T1 (de) † 2007-10-02 2012-05-15 Inst Nat Sante Rech Med Für humanes hepcidin spezifische antikörper
WO2009097461A1 (en) 2008-01-29 2009-08-06 Neoguide Systems Inc. Apparatus and methods for automatically controlling an endoscope
WO2010065815A2 (en) † 2008-12-05 2010-06-10 The Regents Of The University Of California Mini-hepcidin peptides and methods of using thereof
BR112014013697A2 (pt) 2011-12-09 2020-11-03 The Regents Of The University Of California peptídeos mini-hepcidina modificados e métodos de uso dos mesmos
KR20170002414A (ko) 2014-04-07 2017-01-06 멀겐져 바이오텍, 아이엔씨. 헵시딘 모방 펩티드 및 그 용도
AU2015279571A1 (en) 2014-06-27 2017-02-02 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof

Similar Documents

Publication Publication Date Title
EP1105422B1 (en) Hepatitis c inhibitor peptides
US6767991B1 (en) Hepatitis C inhibitor peptides
JP4452401B2 (ja) Ｃ型肝炎ウイルス阻害ペプチドアナログ
JP2008522617A5 (enExample)
WO1999007733A2 (en) Hepatitis c inhibitor peptides
JP2004525097A5 (enExample)
JP2008502301A (ja) ペプチドの抱合
JP2007535910A5 (enExample)
JP2004521123A5 (enExample)
JP2012526789A (ja) インターフェロンをｐｅｇで標識する方法
JP2002522508A5 (enExample)
MXPA04005891A (es) Proteinas envolventes del virus de hepatitis c purificadas para diagnostico y uso terapeutico.
JP2007536910A5 (enExample)
JP7862685B2 (ja) 新規なｇｌｐ－１、ｇｉｐ、及びグルカゴン受容体の全てに対して活性を有する三重活性体並びにそれを含む肥満の予防又は治療用薬学的組成物
CN101883784B (zh) N-端修饰的干扰素-α
JP2011501675A5 (enExample)
JP2007326781A (ja) 抗ｓａｒｓウイルス剤
JP2011515471A5 (enExample)
JP2024516605A5 (enExample)
JPH06220090A (ja) ポリペプチド
WO2002055548A3 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
JP2005500390A5 (enExample)
CN1766115A (zh) 肿瘤血管导向肽与人干扰素α－2b的融合蛋白的制备方法
CA2782624C (en) Therapeutic use of protein-polymer conjugates
TW202604565A (zh) 用於預防或治療心血管疾病之三重ｇｌｐ－１／ｇｉｐ／升糖素受體促效劑及包含該促效劑之醫藥組成物